Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is an observational study in patients with POAG or OHT that will collect data on the use
of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting.
Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after
baseline, as per normal clinical practice.